Ganga Pharmaceuticals Ltd
Incorporated in 1989, Ganga Pharmaceuticals Ltd manufactures & trades in Pharmaceuticals & allied products (Ayurveda)[1]
- Market Cap ₹ 7.09 Cr.
- Current Price ₹ 12.0
- High / Low ₹ 14.8 / 9.35
- Stock P/E 354
- Book Value ₹ 13.2
- Dividend Yield 0.00 %
- ROCE 3.35 %
- ROE 0.37 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.91 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last 3 years: -15.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| 3.08 | 2.37 | |
| 2.70 | 2.34 | |
| Operating Profit | 0.38 | 0.03 |
| OPM % | 12.34% | 1.27% |
| 0.17 | 0.25 | |
| Interest | 0.24 | 0.19 |
| Depreciation | 0.05 | 0.05 |
| Profit before tax | 0.26 | 0.04 |
| Tax % | 23.08% | 50.00% |
| 0.19 | 0.02 | |
| EPS in Rs | 0.47 | 0.05 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -89% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 10% |
| 3 Years: | % |
| 1 Year: | 18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Equity Capital | 4.06 | 4.06 |
| Reserves | 1.29 | 1.31 |
| 1.45 | 1.55 | |
| 0.77 | 0.74 | |
| Total Liabilities | 7.57 | 7.66 |
| 0.76 | 0.72 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.09 | 0.09 |
| 6.72 | 6.85 | |
| Total Assets | 7.57 | 7.66 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| -0.31 | -0.18 | |
| 0.37 | 0.28 | |
| -0.29 | -0.10 | |
| Net Cash Flow | -0.22 | 0.00 |
| Free Cash Flow | -0.32 | -0.20 |
| CFO/OP | -66% | -567% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Debtor Days | 126.80 | 126.29 |
| Inventory Days | 296.56 | 332.62 |
| Days Payable | 159.69 | 129.52 |
| Cash Conversion Cycle | 263.68 | 329.39 |
| Working Capital Days | 330.63 | 457.41 |
| ROCE % | 3.35% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Number ・Standalone data |
|
||||||||
| Trade Receivables Turnover Ratio Times ・Standalone data |
|||||||||
| Distribution Network (Super Stockist & Retailers) Number ・Standalone data |
|||||||||
| Patent Products Number ・Standalone data |
|||||||||
| Total Product Portfolio (SKUs) Number ・Standalone data |
|||||||||
Documents
Announcements
- Closure of Trading Window 26 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Mar - Newspaper Publication regarding special window for re-lodgement of transfer and dematerialisation request(s) of physical securities
-
Announcement under Regulation 30 (LODR)-Change in Management
10 Mar - Re-appointment of Mr. Bharat Brijmohan Sharma as MD for three years from April 01, 2026; subject to shareholders' approval.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
10 Mar - Re-appointment of Bharat Brijmohan Sharma as MD for three years from April 1, 2026, subject to members' approval.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jan - Certificate under Reg 74(5) confirming share dematerialization for quarter ended Dec 31, 2025.
Annual reports
Concalls
-
May 2024TranscriptAI SummaryPPT
Business Overview:[1]
GPL is engaged in production of quality Ayurvedic Medicines. Apart from manufacturing, the company is also into marketing and distribution of Ayurvedic Medicines